SG11202105915UA - Methods for treating cancer in models harboring esr1 mutations - Google Patents

Methods for treating cancer in models harboring esr1 mutations

Info

Publication number
SG11202105915UA
SG11202105915UA SG11202105915UA SG11202105915UA SG11202105915UA SG 11202105915U A SG11202105915U A SG 11202105915UA SG 11202105915U A SG11202105915U A SG 11202105915UA SG 11202105915U A SG11202105915U A SG 11202105915UA SG 11202105915U A SG11202105915U A SG 11202105915UA
Authority
SG
Singapore
Prior art keywords
methods
treating cancer
esr1 mutations
models harboring
harboring esr1
Prior art date
Application number
SG11202105915UA
Inventor
Hitisha Patel
Teeru Bihani
Heike Arlt
Nianjun Tao
Original Assignee
Radius Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Radius Pharmaceuticals Inc filed Critical Radius Pharmaceuticals Inc
Publication of SG11202105915UA publication Critical patent/SG11202105915UA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • A61K31/015Hydrocarbons carbocyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SG11202105915UA 2018-12-06 2019-12-06 Methods for treating cancer in models harboring esr1 mutations SG11202105915UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862776338P 2018-12-06 2018-12-06
PCT/US2019/064980 WO2020118202A1 (en) 2018-12-06 2019-12-06 Methods for treating cancer in models harboring esr1 mutations

Publications (1)

Publication Number Publication Date
SG11202105915UA true SG11202105915UA (en) 2021-07-29

Family

ID=69158304

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202105915UA SG11202105915UA (en) 2018-12-06 2019-12-06 Methods for treating cancer in models harboring esr1 mutations

Country Status (14)

Country Link
US (1) US20220016052A1 (en)
EP (1) EP3890835A1 (en)
JP (2) JP7497353B2 (en)
KR (1) KR20210100135A (en)
AU (1) AU2019392908A1 (en)
BR (1) BR112021010141A2 (en)
CA (1) CA3121918A1 (en)
EA (1) EA202191256A1 (en)
IL (1) IL283655A (en)
JO (1) JOP20210138A1 (en)
MA (1) MA54393A (en)
MX (1) MX2021006412A (en)
SG (1) SG11202105915UA (en)
WO (1) WO2020118202A1 (en)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2737496C2 (en) 2015-04-29 2020-12-01 Радиус Фармасьютикалз, Инк. Methods of treating cancer

Also Published As

Publication number Publication date
BR112021010141A2 (en) 2021-08-24
KR20210100135A (en) 2021-08-13
US20220016052A1 (en) 2022-01-20
WO2020118202A1 (en) 2020-06-11
MA54393A (en) 2021-10-13
CA3121918A1 (en) 2020-06-11
EA202191256A1 (en) 2021-10-06
JP2024101017A (en) 2024-07-26
JOP20210138A1 (en) 2023-01-30
JP7497353B2 (en) 2024-06-10
EP3890835A1 (en) 2021-10-13
JP2022511497A (en) 2022-01-31
AU2019392908A1 (en) 2021-06-10
IL283655A (en) 2021-07-29
MX2021006412A (en) 2021-07-21

Similar Documents

Publication Publication Date Title
HK1251407A1 (en) Methods for treating cancer
IL270720A (en) Combination therapies for treating cancer
ZA201706616B (en) Method for treating cancer
IL289947A (en) Method for treating cancer
IL252182B (en) Method for treating cancer
HK1250638A1 (en) Methods for treating egfr mutant cancers
IL273395A (en) Combination therapies for treating cancer
HK1254258A1 (en) Methods for treating cancer using apilimod
IL257691A (en) Method for treating cancer
EP3405203A4 (en) Methods for treating cancer
HK1250944A1 (en) Methods for treating cancer
EP3440112A4 (en) Methods for treating cancer
IL255079A0 (en) Methods for treating lung cancer
EP3271483A4 (en) Methods and materials for assessing and treating cancer
HK1250942A1 (en) Methods for treating cancer
HK1250943A1 (en) Methods for treating cancer
IL248178A0 (en) Methods and kits for identifying pre-cancerous colorectal polyps and colorectal cancer
EP3303289A4 (en) Compounds and methods for treating cancer
IL283655A (en) Methods for treating cancer in models harboring esr1 mutations
SG10201508795XA (en) Method for treating cancer
SG11202007924TA (en) Method for introducing mutations
IL265537A (en) Methods for treating ovarian cancer